Suzanne Drury

Suzanne Drury

Auto-generated profile, based on publicly available information

Suzanne Drury

Congenica Ltd, Biodata Innovation Centre, Wellcome Trust Genome Campus, Hinxton, CB10 1DR, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2016 in Prenatal Diagnosis
Verified
Journal Article
Open access
PDF file
TVTalitha I. Verhoef
Talitha I. Verhoef
MHMelissa Hill
Melissa Hill
SDSuzanne Drury
Suzanne Drury
SMSarah Mason
Sarah Mason
LJLucy Jenkins
Lucy Jenkins
LCLyn Chitty
Lyn Chitty
Objective: Evaluate the costs of offering non‐invasive prenatal diagnosis (NIPD) for single gene disorders compared to traditional invasive testing to inform NIPD implementation into clinical practice.Method: Total costs of diagnosis using NIPD or invasive testing pathways were compared for a representative set of single gene disorders.Results: For autosomal dominant conditions, where NIPD molecular techniques are straightforward, NIPD cost £314 less than invasive testing. NIPD for autosomal recessive and X‐linked conditions requires more complicated technical approaches and total costs were more than invasive testing, e.g. NIPD for spinal muscular atrophy was £1090 more than invasive testing. Impact of test uptake on costs was assessed using sickle cell disorder as an example. Anticipated high uptake of NIPD resulted in an incremental cost of NIPD over invasive testing of £48 635 per 100 pregnancies at risk of sickle cell disorder.Conclusion: Total costs of NIPD are dependent upon the complexity of the testing technique required. Anticipated increased demand for testing may have economic implications for prenatal diagnostic services. Ethical issues requiring further consideration are highlighted including directing resources to NIPD when used for information only and restricting access to safe tests if it is not cost‐effective to develop NIPD for rare conditions. © 2016 The Authors. Prenatal Diagnosis published by John Wiley & Sons, Ltd.

18 October 2016
Verified
Book Chapter
Closed access
PDF file
SDSuzanne Drury
Suzanne Drury
SMSarah Mason
Sarah Mason
FMFiona McKay
Fiona McKay
KLKitty Lo
Kitty Lo
CBChristopher Boustred
Christopher Boustred
LCLyn Chitty
Lyn Chitty

3 April 2014 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
SDSuzanne Drury
Suzanne Drury
CBChristopher Boustred
Christopher Boustred
MTMehmet Tekman
Mehmet Tekman
HSHoria Stanescu
Horia Stanescu
RKRobert Kleta
Robert Kleta
RSRichard H. Scott
Richard H. Scott

2 November 2020 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
PDF file
EDE. Dempsey
E. Dempsey
JPJ. Pryce
J. Pryce
BTBasky Thilaganathan
Basky Thilaganathan
SMS. Mansour
S. Mansour
THT. Homfray
T. Homfray
SDS. Drury
S. Drury

19 March 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
LBLamia Mestek Boukhibar
Lamia Mestek Boukhibar
ECEmma Clement
Emma Clement
WJWendy Jones
Wendy Jones
SDSuzanne Drury
Suzanne Drury
LOLouise Ocaka
Louise Ocaka
HWHywel Williams
Hywel Williams
Background: Rare genetic conditions are frequent risk factors for, or direct causes of, organ failure requiring paediatric intensive care unit (PICU) support. Such conditions are frequently suspected but unidentified at PICU admission. Compassionate and effective care is greatly assisted by definitive diagnostic information. There is therefore a need to provide a rapid genetic diagnosis to inform clinical management. To date, Whole Genome Sequencing (WGS) approaches have proved successful in diagnosing a proportion of children with rare diseases, but results may take months to report or require the use of equipment and practices not compatible with a clinical diagnostic setting. We describe an end-to-end workflow for the use of rapid WGS for diagnosis in critically ill children in a UK National Health Service (NHS) diagnostic setting. Methods: We sought to establish a multidisciplinary Rapid Paediatric Sequencing (RaPS) team for case selection, trio WGS, a rapid bioinformatics pipeline for sequence analysis and a phased analysis and reporting system to prioritise genes with a high likelihood of being causal. Our workflow was iteratively developed prospectively during the analysis of the first 10 children and applied to the following 14 to assess its utility. Findings: Trio WGS in 24 critically ill children led to a molecular diagnosis in ten (42%) through the identification of causative genetic variants. In three of these ten individuals (30%) the diagnostic result had an immediate impact on the individual’s clinical management. For the last 14 trios, the shortest time taken to reach a provisional diagnosis was four days (median 7 days). Interpretation: Rapid WGS can be used to diagnose and inform management of critically ill children using widely available off the shelf products within the constraints of an NHS clinical diagnostic setting. We provide a robust workflow that will inform and facilitate the rollout of rapid genome sequencing in the NHS and other healthcare systems globally. Funding: The study was funded by NIHR GOSH/UCL BRC: ormbrc-2012-1

1 January 2016 in Obstetrical & Gynecological Survey
Verified
Journal Article
Closed access
MHMelissa Hill
Melissa Hill
PTPhilip Twiss
Philip Twiss
TVTalitha I. Verhoef
Talitha I. Verhoef
SDSuzanne Drury
Suzanne Drury
FMFiona McKay
Fiona McKay
LCLyn Chitty
Lyn Chitty
Obstet Gynecol Surv 2016;71(1):13–15 Cystic fibrosis (CF) is a severe, autosomal recessive, multisystem condition affecting the respiratory and digestive systems. It is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene.